Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants

ABSTRACT RWJ-270201 is a novel cyclopentane inhibitor of influenza A and B virus neuraminidases (NAs). We compared the ability of RWJ-270201 to inhibit NA activity of clinical influenza isolates and viruses with defined resistance mutations with that of zanamivir and oseltamivir carboxylate. In NA inhibition assays with influenza A viruses, the median 50% inhibitory concentration (IC50) of RWJ-270201 (approximately 0.34 nM) was comparable to that of oseltamivir carboxylate (0.45 nM) but lower than that of zanamivir (0.95 nM). For influenza B virus isolates, the IC50 of RWJ-270201 (1.36 nM) was comparable to that of zanamivir (2.7 nM) and less than that of oseltamivir carboxylate (8.5 nM). A zanamivir-resistant variant bearing a Glu119-to-Gly (Glu119→Gly) or Glu119→Ala substitution in an NA (N2) remained susceptible to RWJ-270201 and oseltamivir carboxylate. However, a zanamivir-selected variant with an Arg292→Lys substitution in an NA (N2) showed a moderate level of resistance to RWJ-270201 (IC50 = 30 nM) and zanamivir (IC50 = 20 nM) and a high level of resistance to oseltamivir carboxylate (IC50 > 3,000 nM). The zanamivir-resistant influenza B virus variant bearing an Arg152→Lys substitution was resistant to each NA inhibitor (IC50 = 100 to 750 nM). The oseltamivir-selected variant (N1) with the His274→Tyr substitution exhibited resistance to oseltamivir carboxylate (IC50= 400 nM) and to RWJ-270201 (IC50 = 40 nM) but retained full susceptibility to zanamivir (IC50 = 1.5 nM). Thus, drug-resistant variants with substitutions in framework residues 119 or 274 can retain susceptibility to other NA inhibitors, whereas replacement of functional residue 152 or 292 leads to variable levels of cross-resistance. We conclude that RWJ-270201 is a potent inhibitor of NAs of wild-type and some zanamivir-resistant or oseltamivir-resistant influenza A and B virus variants.

[1]  D. Smee,et al.  In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201 , 2001, Antimicrobial Agents and Chemotherapy.

[2]  W G Laver,et al.  Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. , 1998, Journal of medicinal chemistry.

[3]  R. Webster,et al.  How to overcome resistance of influenza A viruses against adamantane derivatives. , 1998, Antiviral research.

[4]  P. Colman,et al.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.

[5]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[6]  H. Jackson,et al.  Oral Oseltamivir in Human Experimental Influenza B Infection , 1999, Antiviral therapy.

[7]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[8]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[9]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[10]  P. Colman,et al.  Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors , 1998, Journal of Virology.

[11]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[12]  A. Osterhaus,et al.  Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies , 2000, Antimicrobial Agents and Chemotherapy.

[13]  D. Smee,et al.  Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities , 2001, Antimicrobial Agents and Chemotherapy.

[14]  R. Sidwell,et al.  Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.

[15]  A. Hay,et al.  Structural characteristics of the M2 protein of influenza a viruses: Evidence that it forms a tetrameric channe , 1991, Virology.

[16]  M. Lawrence,et al.  Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase , 1993, Journal of virology.

[17]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[18]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[19]  J. Montgomery,et al.  Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir , 2001, Antimicrobial Agents and Chemotherapy.

[20]  N R Taylor,et al.  Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. , 1998, Journal of medicinal chemistry.

[21]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[22]  N. R. Taylor Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. Part 2. Crystallographic and Molecular Modeling Study of Complexes of 4-Amino-4H-pyran-6-carboxamides and Sialidase from Influenza Virus Types A and B. , 1998 .

[23]  P. Colman,et al.  Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.

[24]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[25]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[26]  H. Jackson,et al.  Management of Influenza , 2000 .

[27]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[28]  A. Monto,et al.  Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.

[29]  Paul W Smith,et al.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.